Trump called on Congress to pass a series of measures aimed at lowering drug prices and health insurance costs in his ...

Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools ...

Sanofi Chief Executive Paul Hudson said on Wednesday the company is likely to see some weakness in U.S. vaccine demand this ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

According to Pfizer Inc. (NYSE:PFE), the BREAKWATER study shows statistically significant and clinically meaningful results, ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

At Pfizer, the certification recognises the company’s Analytics Gateway and broader data science ecosystem, where teams work ...

Trump did keep to GOP health orthodoxy with his push to reimburse insurers for cost-sharing reductions, which insurers must give to low-income Obamacare consumers to pay down out-of-pocket costs like ...